Cover Image




Giant cell tumor is a benign aggressive bone         tumor of obscure origin presenting in between second and fourth decade of life, accounts for 4-5percent of primary bone tumors and about 20 percent of benign bone tumors.              Worldwide significantly higher incidence rates are observed in

Asia, where it constitutes about 20percent of all primary bone tumors in China. It is slightly more common in females, has predilection for the epiphyseal metaphyseal region of long bones. After distal femur and proximal tibia, distal radius is the most common site of occurrence for GCT. This site has further distinction of having more aggressive behaviour of GCT with higher chances of recurrences and malignant   transformation. Treatment options for GCT at this site include intraleisonal curettage with bone grafting or cementing,            sandwich technique, adjuvant treatment with Bisphosphonate Irrigation therapy, en bloc excision and reconstruction with non vascular or vascularised fibular autograft, osteoarticular allograft, ulnar translocation,endo prosthesis, custom mega prosthesis. Although amputation would seem likely to be  curative, it is seldom warranted in a tumour that rarely             metastasizes.4 patients with mean age of 21years, with either Campanacci grade I, II or III histopathologically proven giant cell tumors of distal end radius were treated with wide             excision with 2-3cm margin clearance and transverse              osteotomy of proximal radius and reconstruction with                        ipsilateral nonvascularised proximal fibular autograft. Host graft junction was stabilised with Asian DCP in all cases. Wrist ligament reconstruction and fixation of the head of the fibula with carpal bones and distal ulna using K-wires and primary cancellous iliac crest grafting at graft host junction was done in all cases.The follow-up ranged from 14 to 20months. At last follow-up, the average combined range of motion was 100.5degrees with range varying from 60 to 125degrees. The average union time was 7.5months (range 4 to 12months). There was no case of graft fracture,                  metastasis, death or significant donor site morbidity.                Conclusion, Enbloc resection of giant cell tumor of the distal end radius is widely accepted method. Reconstruction with nonvascularised fibular graft, internal fixation with Asian DCP

with primary corticocancellous bone grafting with transfixation of fibular head minimises the problem and gives satisfactory            functional outcome.



Full Text:



Szendroi M. Giant cell tumor of bone. J Bone Joint Surg Br 2004;86:5-12.

Smith RJ, Mankin HJ. Allograft replacement of distal radius for giant celltumor. J Hand Surg Am 1977;2:299-309.

O’Donnell RJ, Springfield DS, Motwani HK, Ready JE, Gebhardt MC, Mankin HJ. Recurrence of giant cell tumors of the long bones after curettage and packing with cement. J Bone Joint Surg Am 1994;76:1827-33.

Rock MG. Curettage of giant cell tumour of bone. Factors influencing local recurrences and metastasis. ChirOrganiMov 1990;75:204-5.

Lackman RD, McDonald DJ, Beckenbaugh RD, Sim FH. Fibular reconstruction for giant cell tumour of the radius. ClinOrthop 1987;218:232- 8.

Dhammi IK, Jain AK, Maheshwari AV, Singh MP. Giant cell tumors of lower end of the radius: problems and solutions. Indian J Orthop 2005;39:201-5.

Campanacci M. Giant cell tumor and chondrosarcoma: grading, treatment and results. Cancer Res 1976;54:257-61.

Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures aftersurgical treatment of tumors of the musculoskeletal system. ClinOrthop 1993;241-6.

Hsu RW, Wood MB, Sim FH, Chao EY. Free vascularised fi bulargrafting for reconstruction after tumour resection. J Bone Joint Surg Br 1997;79:36-42.

Smith RJ, Mankin HJ. Allograft replacement of distal radius for giant celltumor. J Hand Surg Am 1977; 2:299-308.

Lackman RD, McDonald DJ, Beckenbaugh RD, Sim FH. Fibular reconstruction for Giant cell tumour of the radius. ClinOrthop 1987;218:232-8.

Su YP, Chen WM, Chen TH. Giant cell tumors of bone: an analysis of 87 cases.IntOrthop 2004;28:239-43.

Murray JA, Schlafl y B. Giant cell tumors in the distal end of the radius. Treatment by resection and fi bularautograftinterpositionalarthroplas ties. J Bone Joint Surg Am 1986;68:687-94.

Parrish FF. Treatment of bone tumors by total excision and replace ment with massive autologous and homologous grafts. J Bone Joint Surg Am 1966;48:968-90.

Pho RWH. Malignant giant cell tumor or the distal end or the radius treated by a free vascularized fi bular transplant. J Bone Joint Surg Am 1981;63:877-84.

Unni KK. General aspects and data on 11087 cases. In: Dahlins’ Bone Tumors. 5th ed. Philadelphia: Lippincott-Raven Publishers, 1996:263-87.

Mund DF, Yao L, Fu YS, Eckardt JJ. Case report 826: physiological resorption of allograft simulating recurrent giant cell tumor. Skeletal Radiol 1994;23:139-41.

Starr DE. Congenital absence of radius; method of surgical correction. J Bone Joint Surg 1945;27:572.

Kocher MS, Gebhardt MC, Mankin HG. Reconstruction of the distal aspect of the raduis with the use of osteoarticular allograft after excision of skeletal tumour. J Bone Joint Surg 1998;407:419.

Murray JA, Schlafl y B. Giant cell tumors in the distal end of the radius.Treatment by resection and fi bular autograftinterpositionalarthroplasties.J Bone Joint Surg Am 1986;687:94.

Thomas, D. M., & Skubitz, T. (2009). Giant-cell tumour of bone. Current Opinion in Oncology , 21, 338-344.

Southern Medical University, Guangzhou, Guangdong 510515, PR China. Electronic address: Medical Hypotheses (Impact Factor: 1.15). 08/2013;DOI: 10.1016/j.mehy.2013.08.002Source: PubMed

Indian J Orthop. 2007 Apr-Jun; 41(2): 151–153.doi: 10.4103/0019-5413.32048. PMCID: PMC2989140,Multicentric giant cell tumor around the knee Anil Salgia, SK Biswas, Rahul Agrawal, and Vishavdeep Goyal

Giant Cell Tumour of the Distal Radius: Wide Resection and Reconstruction by Non-vascularised Proximal Fibular Autograft Ayman Abdelaziz Bassiony,1MD

J Bone Joint Surg Am. 1996 Feb;78(2):204-11 . Donor-site morbidity with use of vascularized autogenous fibular grafts. Vail TP1, Urbaniak JR1Duke University Medical Center, Durham, North Carolina 27710, USA.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An Initiative of The Tamil Nadu Dr MGR Medical University